tbuckley/cabot-search huggingface dataset:
A critical appraisal of mitogen-induced lymphocyte proliferation in depressed patients
Authors: D F Darko, N W Wilson, J C Gillin, S Golshan
Journal: American Journal of Psychiatry (1991)

The authors' goal was to evaluate the utility of mitogen-induced lymphocyte proliferation assays in clinical research in psychoimmunology.They examined 23 depressed patients and 23 matched comparison subjects with this assay. There were no significant differences between these groups. They then combined the results of this study with the results of their previous study of 20 depressed patients and 20 comparison subjects to examine possible determinants of lymphocyte proliferation in depression.Depressed patients with lower proliferative responses than their matched comparison subjects had lower depression subscale, anergia subscale, and total scores on the Brief Psychiatric Rating Scale than did patients with higher proliferative responses than their matched comparison subjects. This finding was unexpected and unexplained. Depressed patients with lower proliferative responses than their matched comparison subjects also had fewer obsessions and compulsions and less psychomotor agitation according to the Schedule for Affective Disorders and Schizophrenia interview than did patients with higher proliferative responses than their matched comparison subjects. Stepwise discriminant analysis and cluster analysis contributed little further understanding of the determinants of in vitro lymphocyte proliferation of cells from depressed patients.Longitudinal studies using multiple serial determinations of mitogen-induced lymphocyte proliferation are the minimal design needed to make this assay useful in further evaluating any immune system changes in depression.
BETA BLOCKER DOSAGE AND USE OVER TIME IN THE SYSTOLIC HEART FAILURE TREATMENT WITH THE IF INHIBITOR IVABRADINE TRIAL (SHIFT) STUDY
Authors: Jeffrey S. Borer, Karl Swedberg, Michel Komajda, Ian Ford, Luigi Tavazzi, Michael Boehm, Fabienne Dominjon, Juan Maya, Yuna Wu
Journal: Journal of the American College of Cardiology (2015)
P4-19-02: A Population-Based Study of Contemporary Systemic Therapy for Male Breast Cancer.
Authors: KL Bradley, D Villa, CH Speers, R Woods, S Tyldesley
Journal: Cancer Research (2011)

Abstract Purpose: To describe the contemporary utilization, effectiveness and tolerability of tamoxifen, aromatase inhibitors, and trastuzumab in the treatment of early and advanced male breast cancer at a population level in British Columbia. Patients and Methods: Records of 158 consecutive referred cases of invasive male breast cancer diagnosed from January 2000 to March 2010 were analyzed in a population-based cancer program with respect to patient and tumour characteristics, usage of endocrine agents, toxicity and medication adherence, trastuzumab usage and outcome. This group was compared to a population-based random sample of 1000 contemporary female breast cancer patients for prognostic and demographic factors. Survival outcomes were also compared to a cohort of women, matched 2:1 on prognostic and treatment factors. Results: Pathology was most commonly infiltrating ductal carcinoma (94.3%) and estrogen-receptor positive (98.7%). Males were older (median 69.5 years) compared to women (median 60 years). Stage distribution was I (25.3%), II (43.0%), III (24.7%) and IV (7.0%), reflecting more advanced presentation compared to female cases I (43.9%), II (37.9%), III (12.5%) and IV (5.3%). Tamoxifen was prescribed as adjuvant therapy to109 patients, and as palliative therapy to 11. Fourteen (11.7%) patients discontinued tamoxifen due to toxicity. Aromatase inhibitors were prescribed as adjuvant therapy for 16 patients and as palliative therapy for 24; these were discontinued due to toxicity in 5 patients (12.5%). Five of 9 patients known to over-express Her2 were treated with adjuvant chemotherapy with trastuzumab. Overall survival, breast cancer-specific survival and progression-free survival at 5 years were 72.4%, 85.5% and 79.7%, respectively. There was no statistical difference in outcomes compared to the matched female cases. Conclusions: In this large population-based study of contemporary systemic therapy for male breast cancer, outcomes appear to be similar to those of women with the same diagnosis. Side effect profiles, tolerance, adherence and outcomes after tamoxifen, aromatase inhibitors and trastuzumab appear to be similar in men compared to that described in the literature for women. Citation Information: Cancer Res 2011;71(24 Suppl):Abstract nr P4-19-02.
Abstract 5092: Ziv-aflibercept treatment reduces intra-hepatic tumor growth of a preclinical colorectal carcinoma liver metastasis model, monitored using non-invasive micro-ultrasound and bioluminescent imaging.
Authors: Alexander P. Adler, Asma Parveen, Gavin Thurston, Alexandra Eichten
Journal: Cancer Research (2013)

Abstract The liver is a frequent metastatic site for different types of cancers, including colorectal carcinomas (CRC). Therapies that inhibit the angiogenic growth factor VEGF, such as bevacizumab and ziv-aflibercept, are used in combination with chemotherapies to treat metastatic CRC. Ziv-aflibercept (also known as VEGF Trap) is being developed as a part of a collaboration between Sanofi and Regeneron Pharmaceuticals, Inc. and was recently approved by the FDA in metastatic colorectal cancer that is resistant to or has progressed following an oxaliplatin-containing regimen. To better understand the role of VEGF in metastatic CRC, we aimed to assess the effects of ziv-aflibercept on intrahepatic CRC tumor growth, invasion and angiogenesis in a preclinical model. For that we developed and characterized a CRC liver metastasis model that would allow us to longitudinally assess the effects of ziv-aflibercept on CRC growth in the liver parenchyma using non-invasive high frequency micro-ultrasound and bioluminescent imaging modalities. Briefly, luciferase-expressing HCT116 (human colorectal carcinoma) tumor cells were implanted into the left liver lobe of male CB17 SCID mice using image-guided micro-ultrasound. Tumor growth was monitored using both micro-ultrasound and bioluminescent imaging. When tumors were established (approximately 70 mm3), mice were treated with either control protein (hFc, 25 mg/kg, 2x/wk) or ziv-aflibercept (25 mg/kg, 2x/wk) for up to 13 days. Ziv-aflibercept treatment inhibited tumor growth by 95% compared to control treatment. This inhibition of tumor growth was accompanied by significantly decreased cell proliferation (50-70%), as measured by Ki67 immunohistochemistry, and markedly decreased vessel density (approximately 50%), as revealed by CD31 immunohistochemistry. Ziv-aflibercept did not seem to increase tumor invasiveness, as H&amp;E histology did not reveal dramatic differences at the tumor/stroma border between the ziv-aflibercept and control treated tumors. These experiments confirm that ziv-aflibercept reduces growth and vascularity of colorectal tumors growing in the liver in a preclinical model. Citation Format: Alexander P. Adler, Asma Parveen, Gavin Thurston, Alexandra Eichten. Ziv-aflibercept treatment reduces intra-hepatic tumor growth of a preclinical colorectal carcinoma liver metastasis model, monitored using non-invasive micro-ultrasound and bioluminescent imaging. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 5092. doi:10.1158/1538-7445.AM2013-5092
Predictive Value of AKT/MTOR Pathway Immunohistochemical (IHC) Biomarkers for Response to Preoperative Trastuzumab (T) vs Trastuzumab + Everolimus (T + E) in Patients (PTS) with Early Breast Cancer (BC): Unicancer Radher Trial Results
Authors: M. Campone, T. Bachelot, X. Paoletti, J. Merlin, S. Delaloge, D. Loussouarn, J. Bonneterre, M. Jimenez, M. Rios, I. Treilleux
Journal: Annals of Oncology (2013)
MYOCARDIAL ISCHEMIA CAUSED BY CORONARY MICROVASCULAR DYSFUNCTION IS A KEY MECHANISM OF EXERTIONAL ANGINA IN PATIENTS WITH SEVERE AORTIC STENOSIS: INSIGHTS FROM A PROSPECTIVE ADENOSINE-STRESS CARDIAC MAGNETIC RESONANCE STUDY
Authors: Jong-Hwa Ahn, Sung-Ji Park, Sung Mok Kim, Sang-Chol Lee, Seung Woo Park, Jiseok Kang, Minsun Kim, Juwon Kim, Suyeon Lee, Kyunghee Lim, Haseong Chang, Sung Woo Cho
Journal: Journal of the American College of Cardiology (2016)
SINGLE PHOTON EMISSION COMPUTERIZED TOMOGRAPHY IMAGING CAN QUANTIFY REGIONAL DISTRIBUTION OF 99MTECHNETIUM PYROPHOSPHATE UPTAKE IN PATIENTS WITH TRANSTHYRETIN CARDIAC AMYLOIDOSIS
Authors: Ross Ehmke, Rachelle Morgenstern, Adam Castano, Albert DeLuca, Ted Pozniakoff, Jeffrey Lin, Howard Julien, Zhezhen Jin, Andrew Einstein, Mathew Maurer, Sabahat Bokhari
Journal: Journal of the American College of Cardiology (2016)
TCT-140 Prospective Multicenter Registry of 6 Months Dual Antiplatelet Therapy after new Generation Drug-eluting Stent Implantation: ESTROFA-DAPT Study.
Authors: Jose M. De la Torre Hernandez, Juan F. Oteo Dominguez, Felipe Hernandez, Omar Abdul-Jawad Altisent, Fernando Rivero-Crespo, Jose D. Cascon, Antonio L. Arrebola, Federico Gimeno, German Zavala, Leire Andraka, Antonio Gomez Menchero, Francisco Bosa, Xavier Carrillo, Rocio De Lemos, Antonio Ramirez Moreno, Jose L. Castillo, Angel Sanchez-Recalde, Helena Tizon-Marcos
Journal: Journal of the American College of Cardiology (2013)
Abstract 74: The role of epithelial splicing regulatory protein 1 in ovarian cancer
Authors: Chengfu Yuan, Xiaolong He
Journal: Cancer Research (2012)

Abstract Epithelial splicing regulatory protein 1 (ESRP1) is a recently identified cell type-specific splicing factor which has been shown to control an alternative splicing network associated with the epithelial-mesenchymal transition (EMT). Whether ESRP1 play any roles in the development and progression of epithelial ovarian cancer is unknown. To answer this question, we first examined its expression by RT-PCR in a panel of cultured cells including normal ovarian surface epithelial cells (HOSE), immortalized OSE (IOSE398 and IOSE120T) as well as ovarian cancer cell lines A2780, OVCA3, OVCAR5, OVCAR8 and SKOV3. We found that ESRP1was expressed at low levels in HOSE, IOSEs and A2780 cells, at intermediate levels in OVCAR8 and SKOV3 cells and at high levels in OVCAR3 and OVCAR5 cells. Examination of ESRP1 target gene FGFR2 showed that cells with low to intermediate levels of ESRP1 exclusively expressed mesenchymal form of FGFR2 (FGFR2IIIc) while cells with high levels of ESRP1 exclusively expressed epithelial form of FGFR2 (FGFR2IIIb). These results suggest two notions: 1) the switch of FGFR2 splicing occurs in an all-or-none format dependent on the threshold of ESRP1 expression levels; 2) normal ovarian surface epithelial cells may have mesenchymal properties. We also examined the expression of ESRP1 in seven pairs of matched ovarian tumor and adjacent normal tissues and found that ovarian tumors expressed higher levels of ESRP1 than normal tissues in all pairs. In the attempt to clone the entire coding sequence of ESRP1 from SKOV3 cells, we have identified 11 ESRP1 splice variants (SVs). Ectopic expression of four ESRP1 SVs in 293T and A2780 cells, which both have very low levels of endogenous ESRP1, triggered profound apoptosis. The two SVs with exons 14 and 15 skipped appeared more cytotoxic than full-length ESRP1. We are currently investigating the effects of knockdown of ESRP1 on the transformation properties of ovarian cancer cells. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 74. doi:1538-7445.AM2012-74
Ga-67 and I-131 Adosterol Scintigraphic Findings of Bilateral Primary Adrenal Lymphoma
Authors: KAZUYOSHI SUGA, YUKO ISHIKAWA, NAOFUMI MATSUNAGA, KAZUKO MOTOYAMA, AKIKO HARA
Journal: Clinical Nuclear Medicine (2000)

The authors report a rare case of clinically silent bilateral primary adrenal lymphoma (PAL) as imaged by Ga-67 and I-131 adosterol scans. A Ga-67 scan showed symmetric and intense uptake in the masses without abnormal extra-adrenal uptake. After chemotherapy, the scan effectively predicted the subsequent growth of the residual masses despite temporal regression on an abdominal computed tomographic (CT) scan. An I-131 adosterol scan showed positive uptake in both adrenal glands, indicating well-preserved adrenocortical function despite the bilateral masses. Symmetric intense uptake of Ga-67 confined to both adrenal glands seems to suggest this disease, and a Ga-67–avid residual mass after treatment should be carefully managed and will depend on changes in mass size. The assessment of adrenocortical function by an adrenocortical scan seems indispensable in bilateral PAL, because this disease is often associated with adrenocortical insufficiency.
Abstract 1515: Disruption of circadian rhythmicity in liver metastasis of colorectal cancer
Authors: Sander A. Huisman, T.M. van Ginhoven, J.W. van den Berg, H.P. Roest, F. Tamanini, E. Destici, J.N.M. IJzermans, G.T.J. van der Horst, R.W.F. de Bruin
Journal: Cancer Research (2011)

Abstract Background: Liver metastases of colorectal cancer are a major cause of cancer related mortality. Resection of hepatic metastasis prolongs life, but 25% of the functional reserve of the liver should remain after resection to allow adequate liver regeneration. An effective means to downsize the tumor and enable resection is the use of chemotherapeutics. Efficacy and adverse side effects of chemotherapy may vary considerably over a 24 hour period. Chronotherapy (circadian rhythm adjusted chemotherapy) could take advantage of the fact that there may be asynchronies in circadian rhythm between normal and cancer tissue. In addition, genetic or functional disruption of the circadian clock may result in genomic instability and accelerated carcinogenisis and tumor growth. A more thorough understanding of circadian rhytmicity may help in elucidating the role of the clock in tumorigenesis and tumor growth and develop more effective chronotherapeutic chemotherapy treatment schedules. Therefore, in this study we investigated the 24-hour expression levels of key circadian clock genes in colorectal liver metastasis and adjacent healthy liver tissue in the mouse. Materials and methods: Male BALB/c mice were injected with C26 colorectal carcinoma cells into the spleen. Three weeks after tumor inoculation, a hepatectomy was performed at 6 different timepoints over a 24-hour period (n=4 per timepoint) to compare circadian rhythmicity in tumor and adjacent healthy tissue. RNA was isolated and RT-PCR was performed on 5 clock genes: Rev-erbα, Per2, Per1, DBP, and Bmal1 and a clock independent gene induced by feeding (Acss2). Results: Healthy liver tissue showed normal 24-hour oscillations of all 5 clock genes, consistent with normal circadian rhytmicity. In colorectal liver metastasis however, 24-hour oscillations were completely absent in all clock genes except Per2. Per2 oscillations were similar in tumor and adjacent liver tissue, although expression levels in tumor tissue were lower. Since Per2 may also be induced by feeding, we determined the expression of the food induced gene Acss2, which is independent of circadian rhythm. Acss2 levels rose in response to feeding, followed by a rise in Per2, strongly suggesting that the increased expression of Per2 was induced by feeding. Conclusion: Our data demonstrate the absence of circadian rhythm in hepatic metastasis of C26 coloncarcinoma in vivo. The difference between tumor and healthy tissue in this model may provide new clues to further understand the biology, and optimize treatment of hepatic metastasis. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 102nd Annual Meeting of the American Association for Cancer Research; 2011 Apr 2-6; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2011;71(8 Suppl):Abstract nr 1515. doi:10.1158/1538-7445.AM2011-1515
Adjuvant axillary radiotherapy for breast cancer: Is CT planning with nodal contouring better than traditional planning?
Authors: C. Chung, M. Keyes, W. Kwa, L. Weir, C. Parsons
Journal: Journal of Clinical Oncology (2006)

606 Background: Historically, adjuvant radiotherapy planning for breast cancer has been based on clinical mark-up then subsequently bony landmarks. The objective of this study is to investigate whether individualized CT-based nodal contour guided planning of axillary fields in breast cancer improves nodal coverage and minimizes dose to normal tissues. There have been no previous studies addressing this issue. Methods: Thirty 4-field radiotherapy plans were selected as ‘traditional’ plans: 15 without nodal contours (traditional field placement) and 15 with radiation oncologists’ nodal contours. The following structures were contoured on each patient CT, regardless of previously contoured structures: level I, level II/III, supraclavicular(SCV)/infraclavicular(ICV) lymph nodes, ipsilateral brachial plexus and lung. Dose volume histograms (DVHs) of the listed contoured structures were obtained for the 30 original plans. All 30 patients were then re-planned with the same anterior dose prescription as the original plan (4000cGy/16 fractions (#) or 4500cGy/25#) but adjusted depth of midplane dose prescription based on nodal depth; MLC blocking was adjusted to the ‘study’ nodal contours. DVHs of the contoured structures for the new nodal-based plans were compared with the DVHs of the original plans, using two-tailed paired t-tests. Results: Volume receiving 90% dose (V90) was significantly improved for SCV nodes: original plan 84.67% vs nodal plan 95.76%(p=0.0005). V90 were similar for level I and level II/III nodes, but hot spots in these nodal groups were significantly hotter in the original vs nodal plan: mean hot spot for level I 120.8% vs 116.3%(p=0.0008), mean hot spot for level II/III 118.1% vs 113.2% (p=0.000003). Dose to 90% of the brachial plexus (D90) was significantly higher in the original vs nodal plan: 79.92% vs 40.92%(p=0.0028). V20 lung were not significantly different. Mean total body dose was significantly higher in the original vs nodal plan 831.8cGy vs 677.7cGy (p=0.0015). Conclusions: CT-based nodal contour guided planning significantly improves coverage of the nodes, particularly supraclavicular nodes, while markedly reducing the dose to critical normal structures, such as brachial plexus. No significant financial relationships to disclose.
SP0186 Spondyloarthritis: What is new in 2012?
Authors: M. Dougados
Journal: Annals of the Rheumatic Diseases (2013)

THE most important new information in this area of rheumatology is ... the name of the disease (<i>e.g.</i> spondyloarthritis). It has been recognized that the term spondyloarthritis preceded by both the main clinical presentation of the disease (<i>e.g.</i> axial <i>versus</i> peripheral) and for both presentation by the presence or not of radiological structural damage (the current proposal is to use the term "radiographic" in case of demonstration of sacroiliac structural changes [<i>e.g.</i> sub-chondral bone osteosclerosis, joint erosions or fusion] for the axial presentation and the term of "erosive" in case of peripheral presentation). Therefore, in 2012, for example, axial radiographic spondyloarthritis should replace the non appropriate one of "ankylosing spondylitis". Several advances have been achieved recently in the field of spondyloarthritis in terms of either recognition of the disease, physiopathology or treatment. The recently proposed ASAS criteria for both the axial and peripheral presentation of the disease have been evaluated in different sets of patients. All these studies have confirmed the relevance of such sets of criteria and, in particular, have emphasized the relative high frequency of non-radiographic axial spondyloarthritis mainly at an early stage of the disease despite the fact that, at this stage, the burden of the disease is at a similar magnitude than in patients with radiographic axial spondyloarthritis. In terms of physiopathology, improvement has been achieved in a better knowledge of the role of environmental factors not only in terms of microbial environment but also in terms of smoking habits. The still remaining question is whether ossification is a phenomenon resulting from inflammation or whether inflammation and ossification are two independent processes observed in this disease. In terms of therapy, there is the debate of the exact role of physiotherapy (which one? Which "route of administration" [<i>e.g.</i> home exercises <i>versus</i> groups of patients supervised by a physiotherapist ...]). There is also the debate of the mode of administration of NSAID (<i>e.g.</i> on demand) based on the level of the patients symptoms <i>versus</i> continuously whatever the level of patients' symptoms. In case of active disease despite optimal NSAID therapy, TNF blockers have confirmed their short term and long term utility. The possibility to taper or discontinue a TNF blocker in case of persistent remission of the disease is still debated. Finally, drugs with a different mechanism of action (<i>e.g.</i> bisphosphonates, IL6 inhibitors) have failed to demonstrate their utility. At variance, the drugs such as IL17 inhibitors are very promising. In conclusion, dramatic improvements have been achieved in the field of spondyloarthritis coming from the recognition of the disease, the physiopathology to the management of the diseases. <h3>Disclosure of Interest</h3> M. Dougados Grant/Research support from: Abbott, Pfizer, UCB, Lilly,..., Consultant for: Abbott, Pfizer, UCB, Lilly,...
Patiromer in Patients with Kidney Disease and Hyperkalemia Receiving RAAS Inhibitors
Authors: Matthew R. Weir, George L. Bakris, David A. Bushinsky, Martha R. Mayo, Dahlia Garza, Yuri Stasiv, Janet Wittes, Heidi Christ-Schmidt, Lance Berman, Bertram Pitt
Journal: New England Journal of Medicine (2014)

Hyperkalemia increases the risk of death and limits the use of inhibitors of the renin–angiotensin–aldosterone system (RAAS) in high-risk patients. We assessed the safety and efficacy of patiromer, a nonabsorbed potassium binder, in a multicenter, prospective trial.
Early CT Compared With Bone Scintigraphy in Suspected Schapoid Fractures
Authors: Andele de Zwart, Steven J. Rhemrev, Lucas M. kingma, Sven A.G. Meylaerts, Jan-Willem Arndt, Inger B. Schipper, Frank J.P. Beeres
Journal: Clinical Nuclear Medicine (2012)

de Zwart, Andele MS; Rhemrev, Steven J. MD; kingma, Lucas M. MD, PhD; Meylaerts, Sven A.G. MD, PhD; Arndt, Jan-Willem MD, PhD; Schipper, Inger B. MD, PhD; Beeres, Frank J.P. MD, PhD Author Information